Subject(s)
Biliary Tract Diseases/drug therapy , Cefotetan/pharmacokinetics , Cefotetan/therapeutic use , Adult , Aged , Anti-Bacterial Agents/pharmacokinetics , Anti-Bacterial Agents/therapeutic use , Bile/metabolism , Cholelithiasis/blood , Cholelithiasis/drug therapy , Clinical Trials as Topic , Female , Gallbladder/metabolism , Humans , Infections/drug therapy , Male , Metabolic Clearance Rate , Middle AgedABSTRACT
Selective sampling from the main bile way using endoscopic catheterization was used in the attempt to establish parameters capable of identifying patients at risk of septic complications following endoscopic cholangiopancreatography. The results obtained evidenced a significant relationship between neoplastic type obstructions of the main bile way, age of patient and positive bile culture with increased risk of septic complications. The advisability of using local and/or systemic antibiotic prophylaxis in elderly patients with suspected neoplastic obstruction of the bile way and thus candidates for endoscopic cholangiopancreatography is considered.
Subject(s)
Bacterial Infections/etiology , Bile/microbiology , Biliary Tract/microbiology , Cholangiopancreatography, Endoscopic Retrograde/adverse effects , Adult , Aged , Bacteria, Aerobic/isolation & purification , Bacteria, Anaerobic/isolation & purification , Bacterial Infections/microbiology , Biliary Tract/pathology , Biliary Tract Diseases/complications , Biliary Tract Diseases/diagnosis , Biliary Tract Diseases/microbiology , Catheterization , Female , Humans , Male , Middle Aged , Risk FactorsABSTRACT
A randomized clinical study was conducted in order to compare the effectiveness of norfloxacin and cinoxacin in complicated urinary tract infections. Norfloxacin proved effective in 80% of the 40 patients treated, cinoxacin in only 60%.
Subject(s)
Cinoxacin/therapeutic use , Norfloxacin/therapeutic use , Pyridazines/therapeutic use , Urinary Tract Infections/drug therapy , Bacteria/drug effects , Bacteria/isolation & purification , Bacteriuria/drug therapy , Bacteriuria/microbiology , Cinoxacin/pharmacology , Clinical Trials as Topic , Drug Tolerance , Female , Humans , Male , Microbial Sensitivity Tests , Norfloxacin/pharmacology , Random Allocation , Recurrence , Urinary Tract Infections/complications , Urinary Tract Infections/microbiologyABSTRACT
Twelve hospitalised patients, affected by biliary tract infections, were treated with cefotetan at dosages ranging between 4 and 6 g daily i.v. In only 11 patients was the aetiological agent identified. Eleven patients (91.67%) completely recovered from their infections and the pathogens were eradicated; the treatment failed in only 1 patient (8.33%). Furthermore, determinations were made of cefotetan concentrations in serum, gallbladder bile, gallbladder wall and gallstones of 14 patients undergoing cholecystectomy: in 7 patients after only 1 injection i.v. of 2 g and in 7 patients after 7 injections i.v. of 2 g at intervals of 12 h. The levels recorded were several times higher than the minimum inhibitory concentrations against bacteria that are most often responsible for biliary infections. Cefotetan is a promising and effective antimicrobial agent in the therapy of biliary tract infections.